BiotechTV - News

U.S. Science Summit: Patient perspectives with sickle cell patient advocate Jimi Olaghere and cystic fibrosis advocate Bob Coughlin

U.S. Science Summit: Curie.Bio Chairman Alexis Borisy and Parabilis Medicines CEO Mathai Mammen discusses the funding environment for biotech and communicating their work to the public

U.S. Science Summit: Flagship Pioneering Founder & CEO Noubar Afeyan discusses his early days in Cambridge and the opportunities it afforded him, science communication, immigrants, and more

U.S. Science Summit: "Who will shape the future of Bio?" with Recursion President & CEO Najat Khan

The future of medicine relies on integrating artificial intelligence with deep biological insights to decode human health and accelerate drug discovery. By treating biology as a complex, non-linear system rather than a series of isolated targets, AI-driven platforms can significantly reduce the time required to bring i...

U.S. Science Summit: Three science communicator social media all-stars share their stories and offer advice on how to tell science stories that resonate with a broad audience

U.S. Science Summit: BiotechTV's Science Correspondent Chloe Kirk introduces the audience to the science communicator social media all-stars who were in attendance at the summit

U.S. Science Summit: Listen to BiotechTV founder Brad Loncar's opening remarks at the inaugural U.S. Science Summit

U.S. Science Summit: Three leading biotech CEOs share the latest on biotech innovation and discuss how the United States can stay on top of an increasingly competitive global landscape

U.S. Science Summit: Dr. Elias Zerhouni discusses the source of what made the United States strong in medical research decades ago and what is at stake to keep supporting it today

ASCO 2026: Fresh off an IPO, Eikon Therapeutics Chairman & CEO Roger Perlmutter describes the scientific idea behind the company, and walks us through the leading programs

ASCO 2026: "The results that we presented from the RASolute 302 trial are unprecedented." - The CEO behind this year's pancreatic cancer breakthrough walks us through the full results and implications

London based Cytospire Therapeutics has announced an $83M series A financing to develop first-in-class pan-gamma delta T-cell engagers - the lead program is an EGFR targeting solid tumors

Replimune's Chairman discusses FDA's polarizing decision to not approve the company's melanoma treatment after a new review. He says they have filed a FOIA request to learn more about FDA's process

Invivyd develops monoclonal antibodies to prevent or treat infectious diseases. This approach could be useful in tamping down the measles outbreaks that have been occurring due to under-vaccination

Bay Area based Epia Neuro exited stealth earlier this month with the goal of developing a device implanted in the skull that could act as an interface to a glove to helps stroke survivors regain grip

Peter Hotez discusses tropical disease, the importance of science communication, career advice for young scientists, and more

Physican and Biotech Investor Adam May reacts to this morning's 52 week Rezpeg data in alopecia from Nektar

10x Genomics today is announcing Atera, its new in situ spatial transcriptomics platform

Is this analyst the world's biggest bear on the weight loss space? After downgrading Lilly to a sell rating, HSBC's Rajesh Kumar discusses why he thinks pricing factors are being under-appreciated

Raymond James Biotech Innovation Symposium: Biotech analyst Tiago Fauth shares his read on the mood of investors and discusses companies he covers